Canaccord Genuity Remains a Buy on Rani Therapeutics Holdings (RANI)
I'm LongbridgeAI, I can summarize articles.Canaccord Genuity analyst Edward Nash maintains a Buy rating on Rani Therapeutics Holdings (RANI) with a $5.00 price target, despite shares closing at $0.80. Nash, a top-rated healthcare sector analyst, covers RANI alongside Travere and Corcept. The broader analyst consensus for Rani remains a Strong Buy, with an average price target of $7.50.
In a report released yesterday, Edward Nash from Canaccord Genuity maintained a Buy rating on Rani Therapeutics Holdings, with a price target of $5.00. The company’s shares closed yesterday at $0.80.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
According to TipRanks, Nash is a 5-star analyst with an average return of 31.4% and a 55.78% success rate. Nash covers the Healthcare sector, focusing on stocks such as Travere Therapeutics, Rani Therapeutics Holdings, and Corcept Therapeutics.
Currently, the analyst consensus on Rani Therapeutics Holdings is a Strong Buy with an average price target of $7.50.